Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
PaperCitations, authors & open-access status
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 87 citations, 2018 year and bronze oa status.
87
Citations
2018
Year
bronze
OA Status